Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data

Authors

• G. Lopes
• J. Gainor
• V. Subbiah
• D. Bowles
• R. Doebele
• A. Mansfield
• C. Baik
• Shirish M. Gadgeel, Henry Ford HealthFollow
• G. Kalemkerian
• S-H. I. Ou
• C. Becerra
• M. Evangelist
• S. Liu
• J. Melear
• A. Saxena
• A. Thomassen
• S. Wang
• B. Besse

Recommended Citation

Lopes G, Gainor J, Subbiah V, Bowles D, Doebele R, Mansfield A, Baik C, Gadgeel SM, Kalemkerian G, Ou SI, Becerra C, Evangelist M, Liu S, Melear J, Saxena A, Thomassen A, Wang S, Besse B. Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data. J Thorac Oncol 2025; 20(10):2.

Document Type

Conference Proceeding

Publication Date

9-9-2025

Publication Title

J Thorac Oncol

Keywords

NSCLC, RET inhibitor, Oncology, Respiratory System

Volume

20

Issue

10

First Page

2